Monitor shareholder vote on June 18, 2026 for the remaining $2.5M tranche, and watch for human clinical trial commencement in July 2026. No revenue or earnings data to evaluate fundamentals.
Price Chart
Executive Summary
Gelteq provided a corporate update on its pipeline progress, including plans to commence a human clinical trial in Q3 2026 and a veterinary clinical trial for an antiparasitic drug. The company also secured up to $3.5M in debt financing, with $1M funded and the remainder subject to shareholder approval. As a pre-revenue biotech with a $13M market cap, these milestones are early-stage and do not provide material financial data.
Key Financial Metrics
Key Facts
- Human clinical trial planning completed, expected to commence next quarter (July 1, 2026).
- Veterinary clinical trial commenced for an antiparasitic drug candidate, with planned FDA application targeted for later in 2026.
- Preclinical diabetes study commenced.
- Signed strategic debt financing of up to $3.5M with an institutional investor; $1M funded, additional $2.5M subject to shareholder approval on June 18, 2026.
- Veterinary palatability trials with Kemin Industries completed, demonstrating strong canine acceptance.
- Commercial product manufactured for a new customer in East Asia, with delivery expected in June 2026.
- Center of Excellence established in Guangdong Province, China.
Financial Impact
Debt financing of up to $3.5M secured; no revenue or earnings reported.
Risk Factors
- Shareholder approval for additional financing may not be obtained.
- Clinical trial outcomes are uncertain and may delay regulatory pathways.
- Pre-revenue stage with limited cash runway; reliance on debt financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3313426 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 30, 2026 16w ago | 6-K | $0.6600 $0.5500 | ▲ +16.67% | ▲ +19.54% | $0.4416 (+33.09%) |
Jun 17, 2026 18w ago | Press Release | $1.14 $0.7001 | ▼ −38.59% | ▼ −41.74% | $0.4416 (−61.26%) |
Jun 12, 2026 19w ago | Press Release | $0.9900 $0.6762 | ▼ −31.70% | ▼ −34.96% | $0.4416 (−55.39%) |
Jun 2, 2026 20w ago | 6-K | $0.4860 $0.5701 | ▼ −17.30% | ▼ −14.81% | $0.4416 (+9.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers